3.22
+2.88%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Whitehawk Therapeutics
From its filings with the US Securities and Exchange Commission
Whitehawk Therapeutics is based in Morristown, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker WHWK. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $7.1m and a net loss of $20.6m. At that date it held total assets of $150.8m and shareholders' equity of $136.3m.
We are a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments. We have deep experience in chemistry, formulation, and drug delivery, as well as research, clinical, and commercial pharmaceutical development, resulting in successfully taking product candidates from the clinic to approval, launch, and commercialization.
In December 2024, we entered into an intellectual property license agreement (the “WuXi License Agreement”) with WuXi Biologics (Shanghai FX) Co., Ltd. (“WuXi Biologics”) for the development and global commercialization of a portfolio of three next generation antibody drug conjugates (“ADCs”) targeting clinically validated, broadly overexpressed tumor antigens in high potential cancer indications with significant unmet need. These ADCs are constructed utilizing an advanced linker-payload platform called CPT113 that has been shown to provide increased stability in blood circulation and deliver targeted release of a Topoisomerase I (“TOP1”) inhibitor payload into cancer cells.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 26 Jun 2018
- Employees
- 23
- Website
- aadibio.com ↗
- Head office
- 2 HEADQUARTERS PLAZA, MORRISTOWN, NJ, 07960
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Caley CasteleinNon-Executive Independent Chairman of the Board$137,999
- Mr. David LennonPresident, Chief Executive Officer, Principal Executive Officer$1.0m
- Mr. Scott GiacobelloChief Financial Officer, Treasurer$807,929
- Adm. (Retd.) David DornanChief Scientific Officer
- Mr. Neil DesaiExecutive Director, since 2021$1.7m
- Mr. Bryan BallChief Technical Operations Officer$648,571
- Dr. Behzad AghazadehIndependent Director$102,499
- Dr. Anupam DalalIndependent Director$112,999
- Dr. Mohammad HirmandIndependent Director$97,999
- Mr. Richard MarounIndependent Director$117,999
- Ms. Emma ReeveIndependent Director$117,999
- Mr. Baiteng ZhaoIndependent Director$107,428
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 34
- Environment
- 39
- Social
- 15
- Governance
- 49
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- FYARRO is an mTOR inhibitor for genetically defined cancers with rapamycin pathway alterations.
- Whitehawk Therapeutics has 23 employees focused on precision therapies for cancer patients.
- PRECISION 1 Phase II study targets TSC1 and TSC2 alterations in tumor-agnostic therapy.
Weaknesses
- Whitehawk Therapeutics has only 23 employees, which may limit operational capacity.
- The company's lead drug FYARRO is still in clinical development stages.
- Limited workforce of 23 employees compared to industry standards in biotechnology.
Opportunities
- FYARRO's indication for malignant PEComa tumors offers a niche market opportunity.
- PRECISION 1 study could expand FYARRO's application to TSC1 and TSC2 patients.
- Biotechnology sector growth in Health Care provides potential for new therapies.
Threats
- Competition from other mTOR inhibitors in the Health Care sector.
- Regulatory challenges for clinical-stage biopharmaceutical companies.
- Market risks associated with developing therapies for rare cancer types.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.